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Background: The role of oral immunosuppressive therapy (OIT) after percutaneous
coronary intervention (PCI) and stenting still remains to be deﬁned. We sought to
evaluate the efﬁcacy and safety of oral administration of sirolimus or prednisone to
prevent in-stent restenosis.
Methods: We undertook a meta-analysis of trials in which PCI-patients were
randomly assigned to OIT or control therapy. The primary endpoint was the composite
of death/myocardial infarction (MI) or target lesion revascularization (TLR).
Secondary endpoints were the composite of death/MI, the individual components of
the primary endpoint and in-stent late lumen loss (LLL) at angiographic surveillance.
Results:We obtained individual data of seven trials enrolling 1,246 patients (OIT, n¼
608 versus control therapy, n¼ 638) with 1,456 coronary lesions. At a median follow-
up of 360 days [interquartile range 360-1440] OIT as compared to control therapy
signiﬁcantly reduced the risk of the composite primary endpoint (hazard ratio [95%
CI]¼ 0.62 [0.39-0.96], P¼ 0.03), without signiﬁcant difference in terms of death/MI
(0.84 [0.46-1.52], P¼ 0.57), death (1.12 [0.61-2.06], P¼ 0.71) and MI (0.67 [0.33-
1.38], P¼ 0.28). OIT as compared to control therapy signiﬁcantly reduced the risk of
TLR (0.55 [0.34-0.89], P¼ 0.01) as well as the degree of in-stent LLL (0.620.65 mm
versus 0.940.70 mm; mean difference 0.32 mm [0.22-0.42], P<0.001). The
proportion of patients complaining side effects associated with OIT was 13.4% and
1.1% permanently discontinued the therapy.
Conclusions: The use of oral immunosuppressive therapy as compared to control
therapy reduces the composite of death/myocardial infarction or target lesion revas-
cularization after stenting without safety issues. The advantage of oral immunosup-
pressive therapy is predominantly related to the lower risk of restenosis after
revascularization.
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Background: In atherosclerotic disease of infrapopliteal arteries, drug-eluting stents
(DES) improve patency rates as compared with plain balloon or bare metal stents
(BMS). However, the clinical impact of DES in this vascular territory remains still
uncertain.
Methods: We undertake an updated meta-analysis of randomized trials investigating
the outcomes of percutaneous revascularization with primary drug-eluting stenting in
patients with atherosclerotic disease of infrapopliteal arteries. We searched Medline,
EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), scientiﬁc
session abstracts and relevant websites. Keywords were: "below the knee", "infra-
popliteal artery", "angioplasty", "drug-eluting stent(s)", "bare metal stent(s)", "trial",
and "randomized trial". Inclusion criteria were: (1) randomized design; (2) intention to
treat analysis; (3) a minimum of 6-month follow-up. Exclusion criteria were: (1)
vessels treated other than infrapopliteal arteries; (2) devices used other than DES, plain
balloon or BMS, and (3) duplicated data. The primary endpoint was target lesion
revascularization (TLR); secondary endpoints were restenosis, amputation and death.
Results: A total of 611 patients from 5 trials were randomly assigned to DES (n¼
294) versus control therapy (plain balloon/BMS, n¼ 307). Overall, median lesion
length was 26.8 mm [IQR 18.2-30.0] with a reference vessel diameter of 2.86 mm
[IQR 2.68-3.00]. At a median follow-up of 12 months [interquartile range 12-36],
DES reduced the risk of TLR (odds ratio [95% Conﬁdence interval] ¼ 0.31
[0.18–0.54], p<0.001), restenosis (0.25 [0.15–0.43], p<0.001) and amputation (0.50
[0.26–0.97], p¼ 0.04) without signiﬁcant difference in terms of death (0.81
[0.45–1.49], p¼ 0.50) versus control therapy.
Conclusions: In focal disease of infrapopliteal arteries, drug-eluting stent therapy
reduces the risk of reintervention and amputation as compared with plain balloon or
bare metal stent without impact on mortality at 1-year follow-up.B254 JACC Vol 62/18/Suppl B j October 27–NoTCT-843
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Background: Drug eluting balloons (DEB) have been developed to overcome the
limitations of drug eluting stent (DES), but clinical results of different studies about
DEB are still not consistent. Thus, we performed a meta-analysis to compare
outcomes of DEB and DES in coronary artery disease (CAD).
Methods: Medline/Web databases were searched for studies comparing DEB and
DES for obstructive CAD, reporting late lumen loss (LLL) and rates for overall
mortality, myocardial infarction (MI), stent thrombosis (ST) and target lesion revas-
cularization (TLR).
Results: Eight studies (1462 patients) were included in the meta-analysis. Compared
with DES, DEB treated patients showed non-signiﬁcantly higher LLL (weighted mean
difference [WMD] 0.32, 95% conﬁdence interval [CI] -0.15 to 0.78, P¼0.18) and non-
signiﬁcantly higher rate of binary restenosis (odds ratio [OR] 1.40 [0.68-2.48],
P¼0.36). Mortality (OR 1.13[0.54-2.37], P¼0.74), MI (OR 0.95, [0.50-1.80],
P¼0.87), ST (OR 1.12, [0.34-4.19], P¼0.77) and TLR rates (OR 1.19[0.60-2.38],
P¼0.61) were similar between the 2 treatments. A pre-speciﬁed meta-regression
analysis showed that LLL WMD and TLR OR were inversely correlated to the
prevalence of diabetes (P<0.0001) and directly correlated to reference coronary
diameters (P<0.001).
Conclusions: The present meta-analysis showed that, in comparison with DES, DEB
use was not followed by signiﬁcantly higher LLL, with similar clinical efﬁcacy and
safety. Thus DEB could be considered a reasonable alternative for interventional
cardiologists to limit the use of DES in selected clinical settings.
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Background: Thrombocytopenia (tcp) is associated with poor clinical outcomes in
patients receiving glycoprotein IIb/IIIa inhibitors (GPI), yet the extent of this risk and
differences between drugs and patient populations are uncertain. We evaluated the risk
of tcp associated with GPI compared to placebo.
Methods: Rate ratios were calculated for tcp (<100,000 platelets/mm3) and severe
tcp (<50,000 platelets/mm3) in 28 randomized large trials (>1000 patients) of GPI
versus placebo involving a total of 123,419 patients. We used meta-analysis tech-
niques to estimate the summary effect across all trials, in pre-speciﬁed subgroups, and
in sensitivity analyses to assess the robustness of the data.
Results: GPI use increases the rate of tcp (RR ¼ 1.63, 99%CI 1.48-1.79) and severe
tcp (RR ¼ 3.51, 99%CI 2.68-4.58). These ﬁnding are consistent by route of admin-
istration. Abciximab, tiroﬁban, xemiloﬁban, orboﬁban, and lotraﬁban demonstrated
signiﬁcantly increased tcp; eptiﬁbitide, lamiﬁban and sibraﬁban had non-signiﬁcant
increases compared to placebo. Patients with STEMI (RR 2.84, 99%CI 2.23-3.61) and
elective PCI (RR 2.78, 99%CI 1.76-4.40) had higher rates of tcp than patients with
nSTE-ACS (RR 1.41, 99%CI 1.25-1.58; p<0.001 for heterogeneity by subgroup).
Conclusions: The administration of GPI compared to placebo was associated with
a 63% increased risk of tcp (<100,000 platelets/mm3), and >3-fold increased risk of
severe tcp (<50,000 platelets/mm3). This corresponds to an average of 10-20 addi-
tional cases of tcp per 1000 patients given GPIs, of which are 6-7 are severe.vember 1, 2013 j TCT Abstracts/POSTER/Meta-Analyses and Reviews
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Background: Recent randomized controlled trials (RCTs) have called into question
whether percutaneous coronary intervention (PCI) reduces death or myocardial
infarction in patients with stable ischemic heart disease (SIHD). However, several of
these trials randomized an unselected group of patients, including those with and
without objective ischemia.
Methods: We performed a meta-analysis of RCTs comparing PCI with medical
therapy (MT) in pts with either ischemia (identiﬁed on non-invasive testing) or
abnormal fractional ﬂow reserve (FFR), to determine whether PCI reduces all-cause
mortality in this high-risk SIHD cohort.
Results: Four RCTs comparing PCI vs. MT in pts with objective ischemia (or FFR-
equivalent) were found; these trials randomized a total of 1,769 pts with f/u from 7
months to 10 years. The point estimate of the hazard ratio (HR) for mortality following
PCI vs. MT varied from 0.33-0.73, with no trial heterogeneity (I2¼0%). Of note, the
documented ischemia cohort of the COURAGE trial (Am Heart J 2012) comprised
48% of the weight of the included studies. Overall, 28/871 (3.2%) PCI pts died
compared with 54/898 MT pts (6.0%), consistent with a signiﬁcant reduction in all-
cause mortality with PCI (HR 0.56; 95% conﬁdence interval (CI): 0.34-0.93, p¼0.02,
Figure), which remained signiﬁcant when 3 other ineligible RCTs were added which
included a PCI vs MT arm (HR 0.61 [0.42,0.89], p¼0.01).JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: Despite conventional conclusions drawn from existing RCT data that
PCI and MT result in comparable survival in SIHD, when analyses are restricted to pts
with objective ischemia (or the FFR equivalent), PCI is associated with a signiﬁcant
and consistent 44% reduction in all-cause mortality compared with MT.
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Background: Studies indicate no clear beneﬁt of early percutaneous coronary inter-
vention (PCI) (<24 hours) in non ST elevation acute coronary syndrome (NSTE-
ACS) patients as compared to delayed PCI (>24 hours). However, high risk NSTE-
ACS patients may beneﬁt from early PCI. We pooled existing data and performed
a meta-analysis.
Methods: Medline, PubMed and abstracts from major cardiology conferences were
searched. Randomized control trials (RCTs) comparing the composite of death and/or
myocardial infarctions (MI) and/or repeat revascularization within 6 months of early
or delayed PCI for high risk patients with NSTE-ACS were included. High risk was
deﬁned as TIMI score >5 or GRACE score >140. The effects of both methods were
analyzed by calculating pooled estimates for death, MI and repeat revascularization.
Analyses were performed for the outcome by using odds ratio (OR) by random effects
model. Heterogeneity among studies was assessed by calculating I00 measure of
inconsistency.
Results: Three studies (ACUITY, ELISA-3 and TIMACS) with a total of 3090
patients met our inclusion criteria. The incidence of the composite of death and/or MI
and/or repeat revascularization was not different between early PCI [207/1422
(14.5%)] as compared to delayed PCI [310/1668(18.6%)], (OR 0.72, 95% CI 0.51-
1.01, P¼0.06).Conclusions: Coronary artery revascularization within 24 hours of presentation does
not reduce composite of death and/or MI and/or repeat revascularization at 6 months
in high risk NSTE-ACS as compared to intervention after 24 hours. More studies are
needed on this subgroup of NSTE-ACS patients.
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Background: Delayed endothelial coverage of stent struts has been linked to late stent
thrombosis, especially after drug-eluting stent implantation. The high-resolution
capability of intravascular optical coherence tomography (OCT) enables visualization
of strut coverage and has been used to quantify coverage at various time points post
implantation. This has the potential application of predicting timing and safety of dual
anti-platelet therapy discontinuation. We aim to summarize all known quantitative
strut level analysis data of clinically implanted coronary stents in human subjects to
date as evaluated by OCT.
Methods: A review of publications and online databases up to February 2013
retrieved 59 eligible articles and abstracts, 1843 initially identiﬁed studies. Data
extracted for bare metal, (BMS), Sirolimus (SES), Paclitaxel (PES), Zotarolimus
(ZES-E & ZES-R) and Everolimus eluting stent (EES) strut coverage and malap-
position was compared between stents at various time intervals post implantation.
Results: 13 abstracts and 46 papers were included in the analysis with studies per-
formed from 1 week to 5 years post implantation. 2,278 patients were studied,
comprising 2,716 stents, 2,044 lesions and strut level data on 532,533 struts, where
data was recorded.
Conclusions: Bare metal stents achieved a threshold of < 2.0% uncovered struts
within 1 month of implantation, SES within 48 months, PES within 60 months,
Endeavor ZES within 2.5 months and EES within 20 months. Resolute ZES have
a 7.4% uncovered strut rate at 13 months post-implantation and lack data beyond this.
OCT enables direct visualization and quantiﬁcation of coronary stent delayed endo-
thelial coverage at a strut level, providing insight into drug eluting stent-speciﬁc
effects on the timing of neo-intimal healing. This may have a role in predicting drug-
eluting-stent speciﬁc safety of dual-antiplatelet therapy cessation.acts/POSTER/Meta-Analyses and Reviews B255
